Today Mylan announced that they had received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Anastrozole tablets, 1 mg, the generic version of AstraZeneca’s Arimidex, a treatment for early breast cancer.

According to IMS Health, Anastrozole tablets had sales in the US of approximately $917 million for the last year ending March 31, 2010 . The product is available for immediate shipment.

Pr Newswire Reported that,

Currently, Mylan has 136 ANDAs pending FDA approval representing $94 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $20.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

This should help those who are struggling to pay for the treatment. If you would like to save even more on Arimidex, join No Prescription Needed today!

Tags: generic arimidex

This entry was posted on Tuesday, June 29th, 2010 at 9:50 am and is filed under Uncategorized, buy drugs online. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.